{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T05:27:21Z","timestamp":1787808441847,"version":"build-2784847793"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T00:00:00Z","timestamp":1733097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T00:00:00Z","timestamp":1733097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"JSPS KAKENHI","award":["JP21K10483"],"award-info":[{"award-number":["JP21K10483"]}]},{"name":"JSPS KAKENHI","award":["JP21K10483"],"award-info":[{"award-number":["JP21K10483"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-81663-w","type":"journal-article","created":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T11:55:59Z","timestamp":1733140559000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Elevated glucagon and postprandial hyperglycemia in fatty liver indicate early glucose intolerance in metabolic dysfunction associated steatotic liver disease"],"prefix":"10.1038","volume":"14","author":[{"given":"Rieko","family":"Oikawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumiko","family":"Nakanishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiji","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asako","family":"Wakasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mizuho","family":"Iwadare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruka Kawanami","family":"Iwao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoko","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunimitsu","family":"Iwai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,2]]},"reference":[{"key":"81663_CR1","first-page":"141","volume":"45","author":"R Matsubara","year":"2021","unstructured":"Matsubara, R. et al. A survey of patients with gout during COVID-19 pandemic. Gout Uric Nucleic Acids. 45, 141\u2013147 (2021).","journal-title":"Gout Uric Nucleic Acids"},{"key":"81663_CR2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","volume":"15","author":"Z Younossi","year":"2018","unstructured":"Younossi, Z. et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat. Rev. Gastroenterol. Hepatol. 15, 11\u201320 (2018).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"81663_CR3","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1007\/s00535-012-0533-z","volume":"47","author":"Y Eguchi","year":"2012","unstructured":"Eguchi, Y. et al. Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study. J. Gastroenterol. 47, 586\u2013595 (2012).","journal-title":"J. Gastroenterol."},{"key":"81663_CR4","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1002\/hep.24001","volume":"52","author":"H Tilg","year":"2010","unstructured":"Tilg, H. & Moschen, A. R. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 52, 1836\u20131846 (2010).","journal-title":"Hepatology"},{"key":"81663_CR5","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1111\/jgh.13264","volume":"31","author":"S Ballestri","year":"2016","unstructured":"Ballestri, S. et al. Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis. J. Gastroenterol. Hepatol. 31, 936\u2013944 (2016).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"81663_CR6","doi-asserted-by":"publisher","first-page":"586","DOI":"10.2957\/kanzo.51.586","volume":"51","author":"Y Kimura","year":"2010","unstructured":"Kimura, Y. et al. Clinical usefulness of glucose tolerance test in nonalcoholic fatty liver disease patients without overt diabetes mellitus. Kanzo 51, 586\u2013588 (2010).","journal-title":"Kanzo"},{"key":"81663_CR7","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3390\/jcm9124049","volume":"9","author":"KD Galsgaard","year":"2020","unstructured":"Galsgaard, K. D. The vicious circle of hepatic glucagon resistance in non-alcoholic fatty liver disease. J. Clin. Med. 9, 40\u201349 (2020).","journal-title":"J. Clin. Med."},{"key":"81663_CR8","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1007\/BF00277486","volume":"31","author":"Y Akanuma","year":"1988","unstructured":"Akanuma, Y., Morita, M., Fukuzawa, N., Yamanouchi, T. & Akanuma, H. Urinary excretion of 1,5-anhydro-D-glucitol accompanying glucose excretion in diabetic patients. Diabetologia 31, 831\u2013835 (1988).","journal-title":"Diabetologia"},{"key":"81663_CR9","doi-asserted-by":"crossref","unstructured":"Wewer Albrechtsen, N. J. et al. Hyperglucagonaemia analysed by glucagon sandwich ELISA: nonspecific interference or truly elevated levels? Diabetologia 57, 1919\u20131926 (2014).","DOI":"10.1007\/s00125-014-3283-z"},{"key":"81663_CR10","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/j.cgh.2009.05.033","volume":"7","author":"AG Shah","year":"2009","unstructured":"Shah, A. G. et al. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver diseases. Clin. Gastroenterol. Hepatol. 7, 1104\u20131112 (2009).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"81663_CR11","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1111\/jdi.12400","volume":"7","author":"T Matsuo","year":"2016","unstructured":"Matsuo, T. et al. Postabsorptive hyperglucagonemia in patients with type 2 diabetes mellitus analyzed with a novel enzyme-linked immunosorbent assay. J. Diabetes Investig. 7, 324\u2013331 (2016).","journal-title":"J. Diabetes Investig"},{"key":"81663_CR12","doi-asserted-by":"crossref","unstructured":"Ohki, T. et al. The effectives of liraglutide in nonalcoholic fatty liver disease patients with type 2 diabetes mellitus compared to sitagliptin and pioglitazone. Sci. World J. 496453 (2012). (2012).","DOI":"10.1100\/2012\/496453"},{"key":"81663_CR13","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","volume":"387","author":"MJ Armstrong","year":"2016","unstructured":"Armstrong, M. J. et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 387, 679\u2013690 (2016).","journal-title":"Lancet"},{"key":"81663_CR14","doi-asserted-by":"publisher","first-page":"G762","DOI":"10.1152\/ajpgi.00476.2011","volume":"302","author":"JL Trevaskis","year":"2012","unstructured":"Trevaskis, J. L. et al. Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice. Am. J. Physiol. Gastrointest. Liver Physiol. 302, G762\u2013G772 (2012).","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"81663_CR15","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s13098-023-01022-z","volume":"15","author":"ZJ Liu","year":"2023","unstructured":"Liu, Z. J. & Zhu, C. F. Causal relationship between insulin resistance and sarcopenia. Diabetol. Metab. Syndr. 15, 46 (2023).","journal-title":"Diabetol. Metab. Syndr."},{"key":"81663_CR16","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.3390\/cells10081958","volume":"10","author":"E Massimino","year":"2021","unstructured":"Massimino, E. The impact of glucose-lowing drugs on Sarcopenia in type 2 diabetes:current evidence and underlying mechanisms. Cells 10, 1958 (2021).","journal-title":"Cells"},{"key":"81663_CR17","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1172\/JCI32752","volume":"118","author":"T Ota","year":"2008","unstructured":"Ota, T., Gayet, C. & Ginsberg, H. N. Inhibition of apolipoprotein B100 secretion by lipid-induced hepatic endoplasmic reticulum stress in rodents. J. Clin. Invest. 118, 316\u2013332 (2008).","journal-title":"J. Clin. Invest."},{"key":"81663_CR18","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1055\/s-0034-1370917","volume":"122","author":"G Aktas","year":"2014","unstructured":"Aktas, G. & Alcelik, A. Association between omentin levels and insulin resistance in pregnancy. Exp. Clin. Endocrinol. 122, 163\u2013166 (2014).","journal-title":"Exp. Clin. Endocrinol."},{"key":"81663_CR19","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1590\/1806-9282.20201005","volume":"67","author":"MA Kosekli","year":"2021","unstructured":"Kosekli, M. A. et al. The association between serum uric acid to high density lipoprotein-cholesterol ratio and non-alcoholic fatty liver disease: the abund study. Rev. Assoc. Med. Bras. 67, 459\u2013554 (2021).","journal-title":"Rev. Assoc. Med. Bras."},{"key":"81663_CR20","first-page":"277","volume":"62","author":"MA Kosekli","year":"2023","unstructured":"Kosekli, M. A. & Gulali, A. Serum uric acid to HDL cholesterol ratio is associated with diabetic control in new onset type 2 diabetic population. Acta Clin. Ctoat. 62, 277\u2013282 (2023).","journal-title":"Acta Clin. Ctoat"},{"key":"81663_CR21","doi-asserted-by":"crossref","unstructured":"Kocak, M. Z. et al. Serum uric acid to HDL-cholesterol ratio is a strong predictor of metabolic syndrome in type 2 diabetes mellitus. Rev. Assoc. Med. Bras. () 65, 9\u201315 (2019). (1992).","DOI":"10.1590\/1806-9282.65.1.9"},{"key":"81663_CR22","first-page":"650","volume":"7","author":"A Gulali","year":"2018","unstructured":"Gulali, A. et al. Mean platelet volume (MPV) as an inflammatory marker in type 2 diabetes mellitus and obesity. Bali Med. J. 7, 650\u2013653 (2018).","journal-title":"Bali Med. J."},{"key":"81663_CR23","first-page":"423","volume":"34","author":"MA Kosekli","year":"2021","unstructured":"Kosekli, M. A. Mean platelet volume and platelet to lymphocyte count ratio are associated with hepatitis B-related liver fibrosis. Eur. J. Gastroenterol. Hepatol. 34, 423\u2013327 (2021).","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"81663_CR24","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/nrgastro.2016.3","volume":"13","author":"ME Rinella","year":"2016","unstructured":"Rinella, M. E. & Sanyal, A. J. Management of NAFLD: a stage-based approach. Nat. Rev. Gastroenterol. Hepatol. 13, 196\u2013205 (2016).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"81663_CR25","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1007\/s00535-012-0704-y","volume":"48","author":"M Yoneda","year":"2013","unstructured":"Yoneda, M. et al. Noninvasive scoring systems in patients with nonalcoholic fatty liver disease with normal alanine aminotransferase levels. J. Gastroenterol. 48, 1051\u20131060 (2013).","journal-title":"J. Gastroenterol."},{"key":"81663_CR26","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1194\/jlr.RA120000924","volume":"61","author":"G Kakiyama","year":"2020","unstructured":"Kakiyama, G. et al. Insulin resistance dysregulates CYP7B1 leading to oxysterol accumulation: a pathway for NAFL to NASH transition. J. Lipid Res. 61, 1629\u20131644 (2020).","journal-title":"J. Lipid Res."},{"key":"81663_CR27","doi-asserted-by":"publisher","first-page":"3863","DOI":"10.3390\/ijms21113863","volume":"21","author":"H Fujii","year":"2020","unstructured":"Fujii, H., Kawada, N. & Japan Study Group of Nafld Jsg-Nafld. The role of insulin resistance and diabetes in nonalcoholic fatty liver disease. Int. J. Mol. Sci. 21, 3863 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"81663_CR28","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.3389\/fphar.2018.01566","volume":"9","author":"W Mu","year":"2018","unstructured":"Mu, W. et al. Potential nexus of non-alcoholic fatty liver disease and type 2 diabetes mellitus: insulin resistance between hepatic and peripheral tissues. Front. Pharmacol. 9, 1566 (2018).","journal-title":"Front. Pharmacol."},{"key":"81663_CR29","doi-asserted-by":"publisher","first-page":"E42","DOI":"10.1111\/hepr.12925","volume":"48","author":"Y Seko","year":"2018","unstructured":"Seko, Y. et al. Insulin resistance increases the risk of incident type 2 diabetes mellitus in patients with non-alcoholic fatty liver disease. Hepatol. Res. 48, E42\u2013E51 (2018).","journal-title":"Hepatol. Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-81663-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-81663-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-81663-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T12:04:39Z","timestamp":1733141079000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-81663-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,2]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["81663"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-81663-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,2]]},"assertion":[{"value":"24 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"29916"}}